JATT vs. CGTX, ATHA, PLX, DTIL, TIL, ATRA, ELUT, CVM, TSBX, and ALVR
Should you be buying JATT Acquisition stock or one of its competitors? The main competitors of JATT Acquisition include Cognition Therapeutics (CGTX), Athira Pharma (ATHA), Protalix BioTherapeutics (PLX), Precision BioSciences (DTIL), Instil Bio (TIL), Atara Biotherapeutics (ATRA), Elutia (ELUT), CEL-SCI (CVM), Turnstone Biologics (TSBX), and AlloVir (ALVR). These companies are all part of the "biological products, except diagnostic" industry.
JATT Acquisition (NYSE:JATT) and Cognition Therapeutics (NASDAQ:CGTX) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, community ranking, analyst recommendations and profitability.
Cognition Therapeutics received 8 more outperform votes than JATT Acquisition when rated by MarketBeat users.
Cognition Therapeutics has a consensus target price of $6.67, indicating a potential upside of 243.64%. Given Cognition Therapeutics' higher probable upside, analysts plainly believe Cognition Therapeutics is more favorable than JATT Acquisition.
48.0% of JATT Acquisition shares are owned by institutional investors. Comparatively, 43.4% of Cognition Therapeutics shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Comparatively, 23.8% of Cognition Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
In the previous week, Cognition Therapeutics had 1 more articles in the media than JATT Acquisition. MarketBeat recorded 2 mentions for Cognition Therapeutics and 1 mentions for JATT Acquisition. Cognition Therapeutics' average media sentiment score of 1.59 beat JATT Acquisition's score of 0.00 indicating that Cognition Therapeutics is being referred to more favorably in the news media.
JATT Acquisition's return on equity of -49.58% beat Cognition Therapeutics' return on equity.
Summary
Cognition Therapeutics beats JATT Acquisition on 6 of the 10 factors compared between the two stocks.
Get JATT Acquisition News Delivered to You Automatically
Sign up to receive the latest news and ratings for JATT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JATT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
JATT Acquisition Competitors List
Related Companies and Tools
